How NovaBridge Biosciences stacks up

NBP · against 553 other Healthcare companies listed in US-listed

Overall

40/ 100

Below the middle of the pack.

Ranked #300 of 554 · scores higher than 45% of peers

Bars: peers in each 10-point band of the overall score

101 peers with an overall score of 40–49, including NBP · Click a bar to see the companies

The four scores behind it

Overall = average of valuation, growth, profitability and safety percentile (categories without data are skipped)

Valuation#253 of 590Score 33 / 100 · beats 50%

Growth—Not enough reported data

Profitability#436 of 558Score 11 / 100 · beats 20%Risk#189 of 597Lower relative risk · safety 75 · beats 68%

Ranking by overall score

Top 5 and the companies ranked around NBP

Rank	Company	Market cap	Overall	Valuation	Growth	Profitability	Risk
1	Arbutus Biopharma CorporationABUS · US-listed	563M USD	97	96	98	99	0 / 2
1	Lakefront Biotherapeutics NVLKFT · US-listed	2.2B USD	97	97	99	93	0 / 2
1	Q32 Bio Inc.QTTB · US-listed	263M USD	97	93	—	98	0 / 2
4	Innoviva, Inc.INVA · US-listed	1.4B USD	94	96	91	93	0 / 2
5	Zevra Therapeutics, Inc.ZVRA · US-listed	625M USD	91	95	99	99	0 / 2

Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score